CardiacAssist, Inc. Receives Health Canada Approval For Its PROTEK Duo Veno-Venous Cannula

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

PITTSBURGH--(BUSINESS WIRE)--CardiacAssist, Inc. today announced that it has received a Class 2 medical device license from Health Canada for its new PROTEK Duo veno-venous cannula. The PROTEK Duo™ is licensed for use as a single cannula for both venous drainage and reinfusion of blood via an internal jugular vein during extracorporeal life support procedures.

Approximately 18,000 people in Canada are diagnosed with Acute Respiratory Distress Syndrome (ARDS) every year. Despite receiving therapy with mechanical ventilation, which is widely considered the standard of care, almost half of those diagnosed with ARDS will die as a result of the disease.1 Veno-venous extracorporeal life support (VV ECLS) is an emerging therapy designed to provide a higher level of support by infusing oxygen directly into the blood using an oxygenator, a medical device that acts as an artificial lung. In one large randomized, controlled clinical trial of 180 adult ARDS patients, the use of advanced VV ECLS therapy was shown to improve the rate of survival free of disability by 34% versus conventional management with mechanical ventilation.2

Hey, check out all the engineering jobs. Post your resume today!

Back to news